On the stock market since 2016, it operates in the world of health and science. It has 60 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 78% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $27.5M a year. A small number, but proof the product has real buyers.
There is $22.1M in the vault; even if every debt were paid off, $21.4M would remain.
Over the last 12 months, company executives reported 13 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $7.7M against $27.5M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 12/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 23/100.
On our five-subject report card, SRTS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SRTS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (46/100) says the stock isn’t cheap.